New drug SYNT-101 enters early safety testing in humans
NCT ID NCT07307274
First seen Jan 09, 2026 · Last updated May 14, 2026 · Updated 21 times
Summary
This early-stage study is testing a new drug, SYNT-101, to see if it is safe and how the body processes it. The study involves 64 healthy adults, including some who are overweight or have obesity. Participants will receive either the drug or a placebo, and researchers will monitor for side effects and measure drug levels in the blood. This study does not aim to treat any condition.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for HEALTHY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Veritus Research
RECRUITINGBayswater, Victoria, Australia
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.